Ticiana Leal, MD, discusses how emerging targeted therapies for extensive-stage small cell lung cancer (ES-SCLC) are showing promising objective clinical outcomes that may surpass those of second-line treatments such as topotecan and CAV regimens, particularly highlighting the need to evaluate specific compounds based on platinum-sensitive vs platinum-resistant disease profiles and the potential role of TIGIT inhibitors in future treatment lines.
Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.
Ariel Lopez-Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.
Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.
Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.
Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or step-up dosing, returning patients to community practices for maintenance dosing, and managing grade 3/4 adverse events related to cytokine release syndrome or neurotoxicity.
Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to refer to an academic center or provide treatment in the community setting and how to manage hospitalization if required.
Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in non-Hodgkin lymphoma compared to other therapeutic indications, such as multiple myeloma and non–small cell lung cancer.
Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management, also addressing other important toxicities.
Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management. They also address other important toxicities.
Dr Graff discusses the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.
Panelists discuss the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.
Panelists discuss how they manage cytokine release syndrome and the necessary pretreatment testing to ensure patient safety and effective therapy.
Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that a 12-month OS is clinically meaningful for this patient population following a median of 2 prior lines of therapy.
Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.
Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence.
Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs trastuzumab emtansine in the context of HER2-positive breast cancer with brain metastases.
Mark R. Litzow, MD, discusses the findings from the ECOG-ACRIN E1910 trial which evaluated blinatumomab added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.
Binod Dhakal, MD, MS, discusses the key takeaways from the CARTITUDE-4 trial which were presented at the 2024 International Myeloma Society Annual Meeting.
Ticiana Leal, MD, discusses how lurbinectedin, a synthetic alkaloid derived from marine sources, exerts its antitumor effects by binding to DNA and disrupting repair mechanisms, highlighting promising efficacy results in the Phase 2 PMO1183 trial, where it achieved a 45% objective response rate (ORR) and an 11.2-month median overall survival in patients with relapsed small cell lung cancer (SCLC).